CANNABINOID COMBINATIONS AND THEIR USE IN THE TREATMENT OF CANCER
Patent Information
- Application Number
- DE602021060191
- Authority / Receiving Office
- DE · DE
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2021-08-31
- Publication Date
- 2026-09-16
- Estimated Expiration
- 2041-08-31
AI Technical Summary
Existing treatments for breast cancer, particularly triple-negative breast cancer (TNBC), are limited due to the heterogeneity of breast cancer cells and the development of resistance mechanisms, leading to side effects and chemotherapy resistance, necessitating the exploration of synergistic cannabinoid combinations to activate multiple anti-cancer mechanisms.
A combination of Δ9-tetrahydrocannabinol (THC), cannabigerol (CBG), cannabinol (CBN), and cannabidiol (CBD) in specific ratios, such as 3.7:1.0:1.9:4.8 or 5.5:1.0:1.3:4.8, is used to treat cancer, particularly breast cancer, demonstrating synergistic effects by inducing cell cycle arrest and apoptosis.
The cannabinoid combinations effectively inhibit breast cancer cell growth with reduced toxicity and resistance, offering a therapeutic approach that amplifies anti-cancer mechanisms and reduces the required dose, minimizing side effects and drug resistance.